Semaglutide and Birth Control: What Women Need to Know

Most people who use semaglutide for weight loss are women. Many of them are also using hormonal birth control. That combination raises a question that deserves a clear, honest answer: does semaglutide interfere with oral contraceptives?

The concern is understandable. GLP-1 medications are known to slow the digestive process, and some medications that pass through the stomach can be affected by that delay. Oral birth control pills are one of the first things women think about when they hear that.

The good news is that the research is more reassuring than the concern suggests. But there are still real, practical considerations worth understanding, especially during the early weeks of treatment.

*This article is for educational purposes only and does not constitute medical advice. Compounded semaglutide is not FDA-approved. Always consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

How Semaglutide Affects Digestion

GLP-1 receptor agonists like semaglutide work through several mechanisms to support weight loss. One of the most well-known is slowing gastric emptying: food, and anything you swallow with it, moves from your stomach into your small intestine more slowly than usual.

This slowdown is actually part of why GLP-1 medications work. It extends the feeling of fullness after meals, reduces appetite, and blunts blood sugar spikes. But it also raises a legitimate pharmacological question: if your stomach empties more slowly, does that affect how oral medications are absorbed?

For many drugs, the answer is that timing shifts slightly. The peak concentration in your bloodstream may arrive later than usual (delayed Tmax), but the total amount absorbed over 24 hours often stays the same. That distinction, between delayed peak and reduced total absorption, matters a great deal for how you interpret the birth control question.

---

Does Semaglutide Reduce How Well Oral Birth Control Works?

Based on the best available clinical evidence, semaglutide does not meaningfully reduce the bioavailability of combination oral contraceptives.

The key study was published in the *Journal of Clinical Pharmacology* (Kapitza et al., 2015, PMID: 25475122). Researchers gave 43 women a standard combination oral contraceptive containing ethinylestradiol and levonorgestrel, once daily for eight days, both before and during steady-state semaglutide treatment. They then measured whether semaglutide changed the total hormone exposure.

This study used FDA-approved branded semaglutide. Compounded semaglutide is not FDA-approved and has not been evaluated in dedicated drug-interaction studies; results from the branded formulation cannot be directly extrapolated to compounded preparations.

The result: bioequivalence was established for both hormones. Ethinylestradiol area under the curve met the prespecified bioequivalence criteria. Levonorgestrel exposure was actually 20% higher during semaglutide treatment, not lower, and that ratio still fell within the accepted bioequivalence range. The peak concentrations (Cmax) were also within bioequivalence criteria for both hormones.

In plain terms: the total hormonal exposure from your pill was not reduced when semaglutide was on board.

A 2025 comprehensive pharmacokinetic review of approved GLP-1 receptor agonists (Min et al., *Drug Design, Development and Therapy*, 2025, PMID: 40330819) and a 2024 systematic review of GLP-1 and oral medication interactions (Calvarysky et al., *Drug Safety*, 2024, PMID: 38273155) both confirmed that clinically significant pharmacokinetic interactions between GLP-1 receptor agonists and oral contraceptives are not well supported by available data.

The Ozempic prescribing information does include a note under Drug Interactions (Section 7) that semaglutide may delay the absorption of orally administered medications due to gastric emptying effects. That language is there because it is a class effect worth flagging in a label. It does not mean oral contraceptives will fail.

---

So Why Do Some Providers Recommend Backup Contraception?

If semaglutide does not reduce oral contraceptive bioavailability, why have you heard recommendations to use backup birth control when starting it?

There are two reasons, and neither is about the drug interaction itself.

First, nausea and vomiting during dose escalation. The most common side effects of semaglutide, especially in the first few weeks as the dose increases from 0.25 mg to 0.5 mg to 1.0 mg or higher, are gastrointestinal. Nausea is very common. Vomiting occurs in some people.

If you vomit within two hours of taking an oral contraceptive pill, standard clinical guidance is to treat that dose as missed. This is a well-established concern with any oral medication, and it applies to birth control the same way it applies to anything else. If you are vomiting regularly during the dose escalation phase, your pill may not be reliably absorbed regardless of what semaglutide does to gastric motility.

Second, GLP-1s can improve fertility, particularly for women with polycystic ovary syndrome (PCOS) or insulin resistance. Some women who previously had difficulty conceiving may find that their cycles regularize as they lose weight. A 2026 clinical review in the *European Journal of Contraception and Reproductive Health Care* (Dilbaz and Ateş, 2026, PMID: 41860479) noted that GLP-1 receptor agonists can improve spontaneous pregnancy rates in women with PCOS through weight reduction and enhanced insulin sensitivity.

If you were previously using oral birth control as the primary method while relying on irregular ovulation as a secondary layer of protection, that calculation may shift as your metabolic health improves. Your prescriber needs to know your full picture.

---

IUDs, Patches, Rings, and Other Non-Oral Methods

If you use a non-oral contraceptive method, the gastric emptying question becomes irrelevant. Methods that work outside the gastrointestinal tract are not affected by semaglutide's effects on digestion.

These include:

• Hormonal IUDs (Mirena, Liletta, Kyleena): Locally acting, absorbed directly into uterine tissue, not dependent on oral bioavailability at all.
• Copper IUDs (Paragard): Non-hormonal, purely mechanical, zero pharmacokinetic interaction.
• Transdermal patches (Xulane, Twirla): Hormones absorb through skin directly into the bloodstream.
• Vaginal rings (NuvaRing, Annovera): Locally released, absorbed through vaginal epithelium.
• Subdermal implant (Nexplanon): Continuous hormone release into the bloodstream, no GI involvement.
• Injectables (Depo-Provera): Administered subcutaneously, no oral absorption step.

The 2026 clinical review by Dilbaz and Ateş specifically recommended that non-oral hormonal methods and long-acting reversible contraception may represent more reliable options during GLP-1 treatment, particularly for patients who experience significant gastrointestinal side effects.

If you are concerned about reliability during the early months of semaglutide treatment, this is worth discussing with your provider.

---

---

What About Tirzepatide?

Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist, a different molecule from semaglutide but in the same broader drug class. It also delays gastric emptying, and the same clinical reasoning applies.

The prescribing information for tirzepatide includes a similar drug interaction note about delayed oral medication absorption. The Dilbaz and Ateş 2026 review treated semaglutide and tirzepatide equivalently in their washout guidance (8 weeks before attempting conception for both). Clinically, the considerations around oral contraceptive use during dose escalation apply to tirzepatide as well, particularly the nausea and vomiting concern during the first several weeks.

There is no evidence tirzepatide reduces oral contraceptive efficacy through a direct pharmacokinetic mechanism, but the class-level precautions apply consistently.

---

What to Discuss With Your Provider

Before starting a GLP-1 medication, bring your current contraceptive method into the conversation. Here are the questions worth raising:

• If you use oral contraceptives: What should you do if you vomit within two hours of taking your pill during the dose escalation phase?
• If you have PCOS or irregular cycles: How might improved metabolic health affect your fertility and your contraceptive needs?
• If you are planning to conceive in the next 6 to 12 months: When should you discontinue semaglutide, given the recommended 2-month washout before trying to conceive?
• If you want the most reliable coverage during the adjustment period: Is switching to a non-oral method worth considering?

These are not alarm-raising questions. They are practical conversations that help your provider give you complete guidance.

---

Frequently Asked Questions

Can semaglutide cause an early miscarriage? Semaglutide is not indicated for use during pregnancy and should be discontinued before conception. Animal studies showed adverse fetal outcomes at therapeutic doses, which is why a 2-month washout before trying to conceive is recommended. There is no clinical evidence that semaglutide causes early miscarriage in humans, but adequate human safety data do not exist. If you conceive while taking semaglutide, stop immediately and contact your provider. See our full article on [semaglutide and pregnancy](/resources/semaglutide-and-pregnancy) for detailed guidance.

Should I stop my birth control while on semaglutide? No. Stopping birth control is not recommended simply because you are taking semaglutide. The evidence shows semaglutide does not reduce the hormonal bioavailability of combination oral contraceptives under normal circumstances. The conversation is about managing GI side effects during dose escalation and whether your current method is the right fit for this phase of treatment, not about stopping protection altogether.

Does semaglutide affect hormones or menstrual cycles? GLP-1 medications can affect menstrual regularity indirectly through weight loss and improvements in insulin sensitivity. Women with PCOS often see cycle normalization as metabolic health improves. Semaglutide does not directly suppress or alter the hormonal axis the way hormonal contraceptives do. For a deeper look at GLP-1 and hormonal health, see our article on [GLP-1 medications, women's hormones, and PCOS](/resources/glp1-medications-women-hormones-pcos).

---

Important Disclaimers

Compounding Disclaimer: Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide and tirzepatide are not the same as, equivalent to, or interchangeable with FDA-approved branded products. Clinical trial and pharmacokinetic data cited in this article (including Kapitza 2015 and the prescribing information for Ozempic, Wegovy, Mounjaro, and Zepbound) refer to FDA-approved branded formulations and may not reflect outcomes from compounded formulations.

Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions, including decisions about contraception, medication interactions, or reproductive planning.

Brand Disclaimer: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Mirena, Liletta, Kyleena, Paragard, Xulane, Twirla, NuvaRing, Annovera, Nexplanon, and Depo-Provera are trademarks of their respective owners. Prescriva is not affiliated with, endorsed by, or sponsored by any of these companies.

Results Disclaimer: Individual results vary. Side-effect profiles, gastrointestinal tolerability during dose escalation, and contraceptive efficacy depend on individual factors and adherence to your prescribed regimen. Results are not guaranteed.

---

*This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider regarding your specific contraceptive needs, medication interactions, and reproductive health goals before starting, stopping, or adjusting any medication.*

---

References

1. Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. *J Clin Pharmacol.* 2015;55(5):497-504. PMID: 25475122.
2. Dilbaz B, Ateş C. The effects of glucagon-like peptide-1 receptor agonists on fertility, contraception, and pregnancy: clinical perspectives. *Eur J Contracept Reprod Health Care.* 2026 Mar 20. PMID: 41860479.
3. Calvarysky B, Dotan I, Shepshelovich D, et al. Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review. *Drug Saf.* 2024;47(5):439-451. PMID: 38273155.
4. Min JS, Jo SJ, Lee S, et al. A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist. *Drug Des Devel Ther.* 2025;19:3509-3537. PMID: 40330819.